Royal Bank of Canada
IDXG

Royal Bank of Canada’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Royal Bank of Canada’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-19
Closed -$9K – 6337
2013
Q2 		$9K Buy
+19
New +$8.62K ﹤0.01% 5321

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KSC
Kendall Square Capital San Francisco, California $4.92M AUM 2.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM

Royal Bank of Canada's IDXG Position: Q3 2013 in Review

Royal Bank of Canada sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2013, closing a stake of 19 shares — an estimated $9K sold.

Royal Bank of Canada first reported a position in IDXG in Q2 2013 and held it in 1 quarter. The position peaked at $9K in Q2 2013. 29 funds tracked by Wall St. Rank hold IDXG as of Q3 2013.

  • Royal Bank of Canada reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Royal Bank of Canada sold 19 Interpace Biosciences, Inc. Common Stock shares in Q3 2013, an estimated $9K.
  • Royal Bank of Canada first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Royal Bank of Canada's Interpace Biosciences, Inc. Common Stock position peaked at $9K in Q2 2013.
  • 29 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2013.

Based on Royal Bank of Canada's 13F filing for Q3 2013, filed 14 Nov 2013.